RxDoctor Payments Data

Geranameo Bullock, MD

Psychiatry · Williamsburg, VANPI 1275821340

Payments from drug & device makers

$768in general payments, 2019–2025

Across 34 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$266
  • Otsuka America Pharmaceutical, Inc.$142
  • AbbVie$135
  • Sunovion Pharmaceuticals Inc.$111
  • Lundbeck LLC$51
  • Neurocrine Biosciences, Inc.$20
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 70th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$116,456
Medicare patients
82
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Chlorpromazine Hcl79$39,531
VraylarCariprazine Hcl16$28,415
Invega SustennaPaliperidone Palmitate12$24,542
Atomoxetine Hcl27$4,487
Divalproex Sodium178$4,392
Oxcarbazepine52$3,475
Lurasidone Hcl19$3,445
Olanzapine105$3,289
Quetiapine Fumarate234$3,035
AmantadineAmantadine Hcl28$2,251
Hydroxyzine Pamoate98$2,220
Venlafaxine Hcl ErVenlafaxine Hcl92$2,017
Risperidone164$1,987
Memantine Hcl16$1,944
Doxepin Hcl17$1,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$135$28,41516 claims
Johnson & JohnsonInvega Sustenna$266$24,54212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →